Linaprazan 通过K+竞争抑制胃中的H+,K+ -ATPase. (IC 50: 1.0 ± 0.2 μM)。Linaprazan对酸有很强的抑制作用。

Linaprazan inhibits gastric H+,K+-ATPase by K+-competitive binding with an IC50 of 1.0 μM.

Linaprazan (AZD0865) can inhibit the final step in acid secretion. Linaprazanreduced porcine renal Na+, K+-ATPase activity by 9 ± 2% [1].

The reference for animal administration is 0.5-1.0 mg/kg. The greater degree of acid suppression with the 75-mg dose of Linaprazan would translate to a healing rate of 89% at 4 weeks [2].

248919-64-4

C21H26N4O2

366.46

AZD0865;利那拉生

DMSO:35 mg/mL (95.51 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years